Panacea Biotec and Refana Partner on COVID-19 Vaccine

New Delhi, India-based Panacea Biotec and Refana USA have teamed up to develop and manufacture a  potential COVID-19 vaccine based on an inactivated virus.

The companies aim to manufacture more than 500 million doses of the vaccine candidate, and they expect more than 40 million doses to be available early next year.

Inactivated viral vaccines “have a higher probability of being safe and efficacious, given their long history and better understanding of their mechanism of action,” said Rajesh Jain, a managing director at Panacea.